Workflow
创新药再迎大利好!北京最新发布
券商中国·2025-04-07 11:53

Core Viewpoint - The article discusses the release of the "Measures to Support the High-Quality Development of Innovative Pharmaceuticals in Beijing (2025)" which includes 32 initiatives aimed at promoting the development of innovative drugs and medical devices in Beijing [1][3]. Group 1: Key Initiatives - The overall time for initiating clinical trial projects will be compressed to within 20 weeks [2]. - Aiming to ensure that the number of newly approved innovative drug and device products will not be less than 15 [2]. - Establishment of a fully automated intelligent biobank for key diseases [2]. Group 2: Implementation and Impact - The measures are expected to provide critical momentum and strategic support for the high-quality development of innovative pharmaceuticals and medical devices, enhancing the confidence of pharmaceutical companies [3]. - The implementation of these measures will shorten the entire innovation cycle from research and development to market application [4]. - The initiatives will promote the digital transformation of pharmaceutical manufacturing and enrich the application scenarios of artificial intelligence in the industry [4]. Group 3: Additional Support Measures - Support for cross-border segmented production for overseas drug marketing authorization holders [5]. - Direct inclusion of nationally negotiated drug products into the medical institution's drug directory [5]. - Development of a 500 billion yuan scale pharmaceutical health industry fund [5].